19 research outputs found
Secondary bacterial flora in patients with pulmonary tuberculosis - a preliminary report
Sputum samples from 100 smear positive or skiagram positive pulmonary tuberculosis patients
were cultured for superinfecting or co-injecting bacteria. These patients were equally divided
into five groups. This included Croup-I who are not treated; Group-II who are treated up
to three months; Group-III who are treated for more than three but less than six months; Group-IV
treated more than six months and lastly Group-V who have completed the prescribed treatment
schedule of varying durations. Neisseria catarrhalis and Strep. viridans predominated in all
patients irrespective of group, other organisms isolated, were Micrococci, E.Coli, Serratia, Proteus
and Pseudomonas. There was no significant difference in the pattern of organisms isolated
from different group of patients. The antibiogram showed the usual susceptibility pattern
Monitoring Peripheral Venous Lactic Acid Levels Is a Meaningful, Effective and Feasible Alternative to Arterial Lactate Levels in Patients with Septic Shock.
Diagnostic efficacy of current imaging tools to detect pulmonary embolism in lung cancer: Correlation with tumor size, histology and anatomical location
Protein kinase C stimulates release of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human decidual cells
Evidence of participation of soluble CD14 in the host response to microbial invasion of the amniotic cavity and intra-amniotic inflammation in term and preterm gestations
Histone Deacetylase in Chronic Lymphocytic Leukemia
<i>Background:</i> Elevated histone deacetylase (HDAC) isoenzyme levels have been described in patients with carcinomas and leukemias. HDAC inhibitors (HDACi) have shown promise in the treatment of carcinomas and are currently under intense research. To make better use of HDACi in treating chronic lymphocytic leukemia (CLL), HDAC isoenzyme levels were studied. <i>Methods:</i> Quantitative reverse transcriptase polymerase chain reaction for HDAC isoenzyme was measured in 32 patients with CLL and compared with 17 normal volunteer controls. ZAP-70, CD38 and CD44 were also assayed and correlated to HDAC isoenzyme levels. <i>Results:</i> The results showed: (1) HDAC isoenzyme levels in CLL were significantly increased in class I including HDAC1 and HDAC3, in class II including HADC6, HDAC7, HDAC9 and HDAC10, and in class III including SIRT1 and SIRT6; (2) higher expression of HDAC isoenzyme levels was found in ZAP-70+ compared to ZAP-70– patients, and CD44 expression levels were correlated with HDAC isoenzyme expression levels in the majority of HDAC classes. <i>Conclusions:</i> These results suggest: (1) in CLL, elevated HDAC isoenzyme activity is not restricted to one class, and therefore, HDACi therapy may need to be directed to more than one specific class of HDAC; (2) higher HDAC expression activity may indicate a poor prognosis and more advanced disease stage (through indirect evidence), since higher values were found in patients with ZAP-70+ and higher CD44 expression levels.</jats:p
